Sifted had the news on Monday morning. Its first line reads: "US-listed medtech Stryker is set to invest around $400m in UK robotic surgery company CMR Surgical in a deal that also gives the American firm an option to acquire it outright." The rest of the piece sits behind a paywall. I should say up front that I read the joint release on Stryker's site instead, datelined Portage, Michigan, and Cambridge, England.
The release names three parts. There is "a strategic equity investment of approximately $400 million (£300 million)" and an "exclusive option for Stryker to acquire the remaining equity of CMR Surgical". The third part is an exclusive US agency deal for the Versius robot. Stryker sells in America. CMR keeps building the product and selling it elsewhere.
One word in the release matters more than the headline figure. The highlights call it a " preferred equity investment". So Stryker's money ranks ahead of ordinary shares. I went looking for the stake size and the price per share in every report I opened, and I found neither.
The Cambridge Independent supplied the reference point. It says CMR's "last official valuation was for $3billion in 2021 during a $600m Series D funding round led by SoftBank and Ally Bridge". Did Stryker pay more or less than that? I cannot tell from these documents. My guess is that the preferred shares exist to protect Stryker if the true value now sits below the 2021 mark, but the companies have not said so and I may be wrong.
The option is what makes this an M&A story. Stryker gets "the opportunity to acquire 100% of CMR Surgical's outstanding equity in the future, subject to the agreement's terms". Those terms are not public. There is no strike price and no expiry date.
The Cambridge Independent asked CMR directly. A representative said "no change of control is taking place at the time of signing" and added that "No timing should be assumed or speculated on." Any later purchase would need approval from CMR's board and its shareholders, the paper reports. I read that as a company guarding its options as firmly as its new investor guards its own.
MedTech Dive filled in the commercial side. CMR won FDA clearance for its latest robot last year, but only for gallbladder procedures in the United States. As of early 2026 it had performed more than 45,000 procedures worldwide, according to a note from J.P. Morgan analyst Robbie Marcus. Stifel's Rick Wise puts CMR roughly second or third in the global installed base.
The field is crowded. Johnson & Johnson won FDA authorisation for its Ottava robot in July 2026, and Medtronic's Hugo was cleared in December 2025, both chasing Intuitive's da Vinci. Wise called the deal "a now or never moment for Stryker to make the decision". Marcus was cooler: "Even with a great selling platform, we don't think Stryker/CMR will be effective at displacing da Vinci in the [U.S.] any time soon."
Andy Pierce, Stryker's group president for Medsurg and Neurotechnology, will join CMR's board. He said Stryker had "evaluated the segment carefully for years". CMR's chief executive, Massimiliano Colella, called the deal "a strong endorsement of the technology, clinical experience and global business we have built".
Closing still needs regulatory approvals. My reading is simple. For about $400m, Stryker bought a board seat, the US sales rights and a call on the whole company, and it can wait to see whether Versius wins more US indications before it pays for the rest. I do not know the strike price, the stake size or how long the option runs. Those 3 numbers decide who got the better deal, and nobody has printed them.